Who owns NEKTAR THERAPEUTICS?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of NKTR from SEC Form 13F filings across 238 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 238 institutions disclosed 35.8M shares of NEKTAR THERAPEUTICS worth $2.50B — about 108.2% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
238
13F holders
$2.50B
value, 2026 filers
108.2%
of shares outstanding (35.8M sh)
75
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of NKTR's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 5.1M | $353.8M | 0.0% | 15.3% | +17.8% |
| 2 | Two Seas Capital LP | 3.1M | $215.9M | 4.3% | 9.4% | +57.8% |
| 3 | BlackRock, Inc. | 2.9M | $205.4M | 0.0% | 8.9% | +324.7% |
| 4 | BVF INC/IL | 2.4M | $166.9M | 4.3% | 7.2% | -6.6% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 1.5M | $104.5M | 0.0% | 4.5% | +25.0% |
| 6 | TWO SIGMA INVESTMENTS, LP | 1.2M | $83.9M | 0.1% | 3.6% | +29.1% |
| 7 | Vestal Point Capital, LP | 1.0M | $69.8M | 1.6% | 3% | +250.9% |
| 8 | MORGAN STANLEY | 936,560 | $65.4M | 0.0% | 2.8% | +42.0% |
| 9 | STATE STREET CORP | 909,679 | $63.5M | 0.0% | 2.8% | +271.7% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 881,306 | $61.5M | 0.0% | 2.7% | +154.1% |
| 11 | Prosight Management, LP | 810,000 | $56.5M | 9.7% | 2.5% | +10.2% |
| 12 | ARMISTICE CAPITAL, LLC | 724,000 | $50.5M | 0.6% | 2.2% | +25.3% |
| 13 | GILDER GAGNON HOWE & CO LLC | 600,873 | $41.9M | 0.4% | 1.8% | +121.1% |
| 14 | MILLENNIUM MANAGEMENT LLC | 478,120 | $33.4M | 0.0% | 1.4% | +18.3% |
| 15 | BRAIDWELL LP | 473,617 | $33.1M | 1.2% | 1.4% | +112.7% |
| 16 | Sofinnova Investments, Inc. | 471,763 | $32.9M | 1.7% | 1.4% | -7.4% |
| 17 | Woodline Partners LP | 470,875 | $32.9M | 0.1% | 1.4% | +13.4% |
| 18 | ORBIMED ADVISORS LLC | 465,346 | $32.5M | 0.6% | 1.4% | +69.2% |
| 19 | UBS Group AG | 428,400 | $29.9M | 0.0% | 1.3% | +33.8% |
| 20 | EMERALD ADVISERS, LLC | 390,158 | $27.2M | 0.6% | 1.2% | -1.1% |
| 21 | LORD, ABBETT & CO. LLC | 381,624 | $26.6M | 0.1% | 1.2% | -5.8% |
| 22 | VANGUARD PORTFOLIO MANAGEMENT LLC | 348,540 | $24.3M | 0.0% | 1.1% | +380.8% |
| 23 | DAFNA Capital Management LLC | 318,380 | $22.2M | 4.2% | 1% | +92.7% |
| 24 | NORTHERN TRUST CORP | 308,531 | $21.5M | 0.0% | 0.9% | +292.5% |
| 25 | Deep Track Capital, LPNEW | 300,000 | $20.9M | 0.3% | 0.9% | new |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.